(Q35884710)

10 August 2017

1 reference

title

Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives (English)

1 reference

10 August 2017

0 references

1 reference

Zeiser R

1

1 reference

10 August 2017

Bertz H

2

1 reference

10 August 2017

Spyridonidis A

3

1 reference

10 August 2017

Houet L

4

1 reference

10 August 2017

Finke J

5

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Bone Marrow Transplantation

10 August 2017

1 reference

10 August 2017

34

1 reference

10 August 2017

11

1 reference

10 August 2017

923-928

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704670

10 August 2017

0 references

cites work

Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Allogeneic stem cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Making the most of mucin: a novel target for tumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Human tumor antigens recognized by T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

7 January 2021

High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

7 January 2021

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

7 January 2021

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

7 January 2021

Graft-versus-myeloma effect in two cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

7 January 2021

Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

7 January 2021

Donor leukocyte infusions for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

1 reference

7 January 2021

Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704670

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704670

1 reference

Dimensions Publication ID

10 August 2017

0 references

1 reference